Table 1.
Patient characteristics at baseline in the randomized trial
| Control N = 73 (%) | Intervention N = 73 (%) | P-values | |
|---|---|---|---|
| Random assignment 73 | |||
| Ipilimunab | 3 (4) | 4 (6) | 0.956 |
| Pembrolizumab | 36 (49) | 38 (52) | |
| Nivolumab | 13 (18) | 11 (15) | |
| Ipilimumab+Nivolumab | 21 (29) | 20 (28) | |
| Age | |||
| Median (range) | 66 (32; 83) | 66 (34; 87) | 0.619 |
| Sex | |||
| Male | 43 (59) | 35 (48) | 0.184 |
| Female | 30 (41) | 38 (52) | |
| ECOG Performance status | |||
| 0 | 52 (72) | 49 (69) | 0.582 |
| 1 | 19 (26) | 19 (27) | |
| 2 | 1 (1) | 3 (4) | |
| Disease stage | |||
| Stage III | 12 (16) | 10 (14) | 0.818 |
| Stage IV | 61 (84) | 63 (86) | |
| Line of therapy | |||
| Adjuvant | 13 (18) | 11 (15) | 0.841 |
| 1st line | 52 (71) | 52 (71) | |
| 2nd line | 6 (8) | 6 (8) | |
| 3rd line | 2 (3) | 4 (5) | |
| Lactate dehydrogenase | |||
| Normal | 51 (76) | 46 (69) | 0.334 |
| Elevated | 16 (24) | 21 (31) | |
| BRAF status | |||
| Mutated | 31 (42) | 32 (44) | 0.710 |
| Wild type | 30 (41) | 27 (37) | |
| Unknown | 12 (16) | 14 (19) | |
| Experience with electronic devices | |||
| None | 0 (0) | 3 (6) | 0.232 |
| A little | 16 (38) | 15 (32) | |
| A lot | 26 (62) | 29 (62) | |
| Educational level | |||
| Primary/lower sec. | 16 (23) | 19 (28) | 0.731 |
| Upper secondary | 2 (3) | 3 (5) | |
| Short cycle tertiary | 15 (22) | 18 (27) | |
| Bachelor | 30 (43) | 23 (34) | |
| Master | 6 (9) | 4 (6) | |